| 000 | 01903 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250517193358.0 | ||
| 264 | 0 | _c20180814 | |
| 008 | 201808s 0 0 eng d | ||
| 022 | _a1471-2407 | ||
| 024 | 7 |
_a10.1186/s12885-017-3981-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHollis, Robert L | |
| 245 | 0 | 0 |
_aEnhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations. _h[electronic resource] |
| 260 |
_bBMC cancer _c01 2018 |
||
| 300 |
_a16 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xtherapeutic use |
| 650 | 0 | 4 |
_aBRCA1 Protein _xgenetics |
| 650 | 0 | 4 |
_aBRCA2 Protein _xgenetics |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xgenetics |
| 650 | 0 | 4 |
_aCystadenocarcinoma, Serous _xdrug therapy |
| 650 | 0 | 4 |
_aDoxorubicin _xanalogs & derivatives |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGenetic Predisposition to Disease |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aNeoplasm Grading |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xtherapeutic use |
| 650 | 0 | 4 | _aPolymorphism, Single Nucleotide |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aMeynert, Alison M | |
| 700 | 1 | _aChurchman, Michael | |
| 700 | 1 | _aRye, Tzyvia | |
| 700 | 1 | _aMackean, Melanie | |
| 700 | 1 | _aNussey, Fiona | |
| 700 | 1 | _aArends, Mark J | |
| 700 | 1 | _aSims, Andrew H | |
| 700 | 1 | _aSemple, Colin A | |
| 700 | 1 | _aHerrington, C Simon | |
| 700 | 1 | _aGourley, Charlie | |
| 773 | 0 |
_tBMC cancer _gvol. 18 _gno. 1 _gp. 16 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12885-017-3981-2 _zAvailable from publisher's website |
| 999 |
_c27945568 _d27945568 |
||